Standard
B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with Dasatinib in cutaneous T-cell lymphoma (CTCL). / Petersen, D L; Krejsgaard, T; Berthelsen, J; Fredholm, S; Willerslev-Olsen, A; Sibbesen, N A; Bonefeld, C M; Andersen, M H; Francavilla, C; Olsen, J V; Hu, T; Zhang, M; Wasik, M A; Geisler, C; Woetmann, Anders; Ødum, Niels.
In:
Leukemia, Vol. 28, 12.06.2014, p. 2109-12.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Petersen, DL, Krejsgaard, T, Berthelsen, J, Fredholm, S, Willerslev-Olsen, A, Sibbesen, NA
, Bonefeld, CM, Andersen, MH, Francavilla, C
, Olsen, JV, Hu, T, Zhang, M, Wasik, MA
, Geisler, C, Woetmann, A & Ødum, N 2014, '
B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with Dasatinib in cutaneous T-cell lymphoma (CTCL)',
Leukemia, vol. 28, pp. 2109-12.
https://doi.org/10.1038/leu.2014.192APA
Petersen, D. L., Krejsgaard, T., Berthelsen, J., Fredholm, S., Willerslev-Olsen, A., Sibbesen, N. A.
, Bonefeld, C. M., Andersen, M. H., Francavilla, C.
, Olsen, J. V., Hu, T., Zhang, M., Wasik, M. A.
, Geisler, C., Woetmann, A., & Ødum, N. (2014).
B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with Dasatinib in cutaneous T-cell lymphoma (CTCL).
Leukemia,
28, 2109-12.
https://doi.org/10.1038/leu.2014.192Vancouver
Petersen DL, Krejsgaard T, Berthelsen J, Fredholm S, Willerslev-Olsen A, Sibbesen NA et al.
B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with Dasatinib in cutaneous T-cell lymphoma (CTCL).
Leukemia. 2014 Jun 12;28:2109-12.
https://doi.org/10.1038/leu.2014.192Author
Petersen, D L ; Krejsgaard, T ; Berthelsen, J ; Fredholm, S ; Willerslev-Olsen, A ; Sibbesen, N A ; Bonefeld, C M ; Andersen, M H ; Francavilla, C ; Olsen, J V ; Hu, T ; Zhang, M ; Wasik, M A ; Geisler, C ; Woetmann, Anders ; Ødum, Niels. / B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with Dasatinib in cutaneous T-cell lymphoma (CTCL). In: Leukemia. 2014 ; Vol. 28. pp. 2109-12.
Bibtex
@article{ab7e19dc9b1045778e926d1229d7b070,
title = "B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with Dasatinib in cutaneous T-cell lymphoma (CTCL)",
author = "Petersen, {D L} and T Krejsgaard and J Berthelsen and S Fredholm and A Willerslev-Olsen and Sibbesen, {N A} and Bonefeld, {C M} and Andersen, {M H} and C Francavilla and Olsen, {J V} and T Hu and M Zhang and Wasik, {M A} and C Geisler and Anders Woetmann and Niels {\O}dum",
year = "2014",
month = jun,
day = "12",
doi = "10.1038/leu.2014.192",
language = "English",
volume = "28",
pages = "2109--12",
journal = "Leukemia",
issn = "0887-6924",
publisher = "nature publishing group",
}
RIS
TY - JOUR
T1 - B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with Dasatinib in cutaneous T-cell lymphoma (CTCL)
AU - Petersen, D L
AU - Krejsgaard, T
AU - Berthelsen, J
AU - Fredholm, S
AU - Willerslev-Olsen, A
AU - Sibbesen, N A
AU - Bonefeld, C M
AU - Andersen, M H
AU - Francavilla, C
AU - Olsen, J V
AU - Hu, T
AU - Zhang, M
AU - Wasik, M A
AU - Geisler, C
AU - Woetmann, Anders
AU - Ødum, Niels
PY - 2014/6/12
Y1 - 2014/6/12
U2 - 10.1038/leu.2014.192
DO - 10.1038/leu.2014.192
M3 - Journal article
C2 - 24919804
VL - 28
SP - 2109
EP - 2112
JO - Leukemia
JF - Leukemia
SN - 0887-6924
ER -
